Clinical Trial

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Trial Details
NCT Number NCT06942767
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 100 participants
Start Date 2025-06
Primary Completion 2026-12 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-27